Dyslipidemia

Intensive systolic blood pressure control led to a large absolute difference in death and HF among patients with abnormal biomarker levels of hscTnT and NTproBNP.

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

George Dangas, MD, PhD, discusses the results of ENVISAGE-TAVI AF and provides perspective into the priorities of investigators as they plan and conduct additional analyses of the trial.

Results of the TWILIGHT-Stent study provide insight into the impact of stent type on effects of ticagrelor monotherapy compared against ticagrelor plus aspirin among patients within the original TWILIGHT trial.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.

A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

Results of MASTER DAPT demonstrate an abbreviated period of DAPT rather than a standard approach preserves ischemic benefits and reduces bleeding risk in patients at a high bleeding risk following stent implantation.

Risk for major bleeding was found to be higher in patients treated with aspirin, ticagrelor compared to aspirin alone.

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

A trio of trials examine whether or not heparin could provide relief of COVID-19 symptoms in patients with varying levels of disease severity.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Peter Toth, MD, discusses the movement towards new agents in treatment of lipid management.

There are several cholesterol lowering drugs available for this patient population.